Johnson Financial Group Inc. Lowers Stake in Gilead Sciences, Inc. $GILD

Johnson Financial Group Inc. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,790 shares of the biopharmaceutical company’s stock after selling 3,855 shares during the quarter. Johnson Financial Group Inc.’s holdings in Gilead Sciences were worth $2,086,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank acquired a new position in Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Ameriprise Financial Inc. raised its stake in shares of Gilead Sciences by 397.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares during the period. Invesco Ltd. raised its position in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.5%

Shares of NASDAQ:GILD opened at $145.21 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The firm has a market cap of $180.27 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.91 and a beta of 0.37. The business has a fifty day simple moving average of $140.15 and a 200 day simple moving average of $126.57.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The company’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio is 46.68%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the sale, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 309,280 shares of company stock worth $43,935,470. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Wolfe Research raised their price objective on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Barclays began coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price objective on the stock. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks Research nudged up Q1 and Q2 2027 EPS estimates and lifted its FY2027 view (Q1 $2.07, Q2 $2.28, FY $9.54), signaling slightly stronger near-term earnings expectations that can support multiple expansion. Zacks Analyst Blog
• Positive Sentiment: Large, unusually active call buying occurred (≈130,626 calls traded, ~1,013% above average), a bullish flow that often precedes upward stock momentum or reflects investor/hedge-fund optimism. (No article link provided)
• Positive Sentiment: Institutional focus on GILD has risen within the Nasdaq-100, which can increase demand from index/quant strategies and boost liquidity and share price support. Gilead Institutional Focus Rises
• Positive Sentiment: Sector commentary remains constructive for large-cap biotech (e.g., Josh Brown saying large-cap biotech can be “growth” plays), which can lift sentiment for Gilead given its scale and drug franchises. Josh Brown commentary
• Neutral Sentiment: Jefferies Financial Group initiated research coverage on Gilead — initiation can be a catalyst but the impact depends on the stance/ratings in the report. Jefferies Coverage Started
• Neutral Sentiment: Gilead’s presentation at Barclays’ Global Healthcare Conference and related transcripts provide investor detail on strategy and pipeline but are informational unless new guidance or data were released. Barclays Conference Transcript
• Neutral Sentiment: Macro commentary notes investors aren’t universally rotating into traditional safe-havens; this broader flow context can mute or amplify healthcare moves but is not a Gilead-specific driver. Macro investor flows

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.